Vasella to leave Novartis in August


Veteran pharma executive Danial Vasella has unexpectedly announced his resignation as chair of the board of directors at Novartis after 17 years at the top of the company.

He will not seek re-election in February, paving the way for a new chair from 1 August. His successor will be Jörg Reinhardt, who is currently running the drug division at Bayer. Vice chair Ulrich Lehner will serve in the interim.

Vasella was chief executive from 1996 to 2010 and became chair in 1999. His resignation as chief executive in 2010 came after a string of attacks by militant animal rights activists aimed at him and his family. The incoming chair, Reinhardt, is a scientist by training, with a PhD in pharmaceutical sciences, who climbed the R&D ranks at Sandoz before the merger with Ciba-Geigy that created Novartis. He arrives at a challenging time for Novartis, which is struggling with the expiry of patents for many of its financially important drugs.


Related Content

Business roundup

26 February 2010 Business

news image

Industry news, March 2010

US Chemical Safety Board chairman resigns

31 March 2015 News and Analysis

news image

Resignation follows accusation of mismangement and exposure of whistleblowers

Most Read

Complex amines made easy (and cheap)

22 May 2015 Research

news image

Iron-catalysed cross-coupling brings together nitroarenes and olefins in a single step in boon for drug makers

Opiate-producing yeast raises spectre of 'home-brewed heroin'

18 May 2015 News and Analysis

news image

Warnings that completion of final steps in opiate biosynthesis could be a double-edged sword

Most Commented

The nuclear danger of iodine

20 May 2015 Comments

news image

It may not be an element you think of as problematic. But, as Mark Foreman explains, iodine causes very complicated problems ...

All set for chemistry

15 May 2015 Feature

news image

Chemistry sets through the years have both weathered and reflected many changes in science and society, as Philip Ball discov...